VIVORYON THERAPEUTICS AG Inactive Instrument
Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2023 | -3.62M -3.91M -5.34M | Sales 2024 * | - | Capitalization | 20.72M 22.39M 30.59M |
|---|---|---|---|---|---|
| Net income 2023 | -28M -30.25M -41.33M | Net income 2024 * | -18M -19.45M -26.57M | EV / Sales 2023 | -53.5 x |
| Net cash position 2023 | 18.52M 20.01M 27.34M | Net cash position 2024 * | 19.55M 21.12M 28.86M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1.11
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics AG
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-06-11
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +24.62% | 44.96B | |
| +1.42% | 42.65B | |
| +45.72% | 41.85B | |
| -4.27% | 29.04B | |
| +11.07% | 26.08B | |
| -20.39% | 19.03B | |
| +6.38% | 12.75B | |
| +28.53% | 12.06B | |
| -3.75% | 11.75B |
